Mar 17, 2021 7:00am EDT Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2
Mar 15, 2021 4:45pm EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 15, 2021 7:00am EDT Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia
Mar 4, 2021 7:00am EST Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 11, 2021 7:00am EST Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
Feb 10, 2021 7:00am EST Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Feb 9, 2021 4:05pm EST Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
Feb 8, 2021 10:30am EST Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
Feb 8, 2021 7:00am EST Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
